Can varenicline (Chantix) be used for vaping cessation in an adult?

Varenicline for Vaping Cessation

Yes, varenicline (Chantix) is effective for vaping cessation in adults and should be used with the same dosing regimen as for smoking cessation: 1 mg twice daily after a one-week titration, combined with behavioral counseling. 1, 2

Evidence Supporting Varenicline for Vaping Cessation

Efficacy in Adults

• A double-blind randomized controlled trial in 140 exclusive daily e-cigarette users demonstrated that varenicline plus counseling achieved 40% continuous abstinence at weeks 4-12 versus 20% with placebo (OR 2.67,95% CI 1.25-5.68, P=0.011). 1
• Long-term abstinence remained superior at weeks 4-24: 34.3% with varenicline versus 17.2% with placebo (OR 2.52,95% CI 1.14-5.58, P=0.0224). 1
• Serious adverse events were infrequent and not treatment-related in this vaping-specific population. 1

Efficacy in Youth and Young Adults

• A 2025 JAMA trial in 261 participants aged 16-25 years who vaped nicotine daily showed even more dramatic results: 51% continuous abstinence with varenicline versus 14% with placebo at weeks 9-12 (adjusted OR 6.5,95% CI 3.0-14.1, P<0.001). 2
• At weeks 9-24, abstinence rates were 28% with varenicline versus 7% with placebo (adjusted OR 6.0,95% CI 2.1-16.9, P<0.001). 2
• The medication was well-tolerated: only 2% of varenicline participants discontinued due to adverse events, with no drug-related serious adverse events. 2

FDA-Approved Dosing Regimen

Use the identical titration schedule approved for smoking cessation: 3

• Days 1-3: 0.5 mg once daily
• Days 4-7: 0.5 mg twice daily
• Day 8 onward: 1 mg twice daily (maintenance dose)

Treatment Duration

• Minimum 12-week course is required for all patients attempting vaping cessation. 4, 3
• An additional 12 weeks (total 24 weeks) is recommended for patients who achieve abstinence to improve long-term quit rates. 4, 3

Timing of Initiation

• Begin varenicline 1-2 weeks before the planned quit date to allow steady-state drug levels. 4
• Alternatively, patients can start varenicline and quit vaping between days 8-35 of treatment. 3

Combining with Behavioral Support

Varenicline must be combined with behavioral counseling for optimal outcomes: 4, 1, 2

• The adult vaping cessation trial combined varenicline with vaping cessation counseling sessions. 1
• The youth trial used weekly counseling plus referral to text messaging support (This is Quitting program). 2
• NCCN guidelines recommend at least four counseling sessions over the 12-week treatment period as minimum standard. 4

Managing Common Adverse Effects

Nausea

• Nausea occurs in 30-43% of users but is typically mild-to-moderate and diminishes with continued therapy. 4, 3
• The one-week titration schedule minimizes nausea compared to non-titrated initiation. 4
• If the standard 1 mg twice-daily dose is not tolerated, permanently reduce to 0.5 mg twice daily, which retains most efficacy while eliminating many adverse effects. 4

Neuropsychiatric Monitoring

• Monitor for new or worsening depression, suicidal thoughts, agitation, and hostility, regardless of prior psychiatric history. 4, 3
• The FDA removed the black-box warning after the EAGLES trial showed no significant increase in neuropsychiatric events versus placebo. 4
• Discontinue varenicline promptly if serious neuropsychiatric symptoms develop. 4

Special Populations

Renal Impairment

• No dosage adjustment needed for mild-to-moderate renal impairment. 3
• For severe renal impairment (CrCl <30 mL/min): start 0.5 mg once daily, titrate to maximum 0.5 mg twice daily. 3
• For end-stage renal disease on hemodialysis: maximum 0.5 mg once daily if tolerated. 3

Hepatic Impairment

• No dosage adjustment necessary for hepatic impairment, as varenicline undergoes minimal hepatic metabolism (92% excreted unchanged in urine). 5, 3

Contraindications and Precautions

• Absolute contraindication: Known history of serious hypersensitivity reactions or skin reactions to varenicline. 3
• Brain metastases constitute an absolute contraindication due to increased seizure risk. 4
• Postmarketing reports include seizures, though rare; use caution in patients with seizure history. 3

Combination with Other Cessation Therapies

Do not combine varenicline with nicotine replacement therapy (NRT) for vaping cessation: 3

• Co-administration of varenicline with transdermal nicotine significantly increased adverse events (nausea, headache, vomiting, dizziness). 3
• In one study, 36% of patients on combination therapy discontinued prematurely due to adverse events versus 6% on NRT alone. 3
• The safety and efficacy of varenicline combined with other cessation therapies have not been established. 3

Clinical Application Algorithm

1. Confirm patient motivation to quit vaping and provide educational materials. 3
2. Set a quit date 1-2 weeks after starting varenicline. 4, 3
3. Initiate standard titration: 0.5 mg daily × 3 days → 0.5 mg BID × 4 days → 1 mg BID. 3
4. Arrange behavioral counseling: minimum 4 sessions over 12 weeks. 4
5. Assess tolerability at 2-3 weeks: reduce to 0.5 mg BID if nausea is intolerable. 5, 4
6. Evaluate cessation status at 12 weeks: if abstinent, continue for additional 12 weeks. 4, 3
7. For treatment failure: consider increasing varenicline dose rather than switching to NRT. 6

Key Pitfalls to Avoid

• Do not skip the titration period—starting directly at 1 mg twice daily markedly increases nausea and discontinuation. 4
• Do not escalate beyond 1 mg twice daily in low-responders; doses up to 5 mg/day do not improve outcomes but significantly increase adverse events. 4
• Do not combine with NRT due to increased adverse events and discontinuation rates. 3
• Do not assume lack of efficacy applies only to cigarette smokers—the evidence now clearly supports varenicline for vaping cessation. 1, 2